Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.48 |
| ▸ | F13A1 | P00488 | 11/20 | 0.48 |
| ▸ | TGM1 | P22735 | 8/20 | 0.48 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447626 | 0.80 | TGM2 (0.49) | TGM2F13A1TGM1TGM3MEN1 | |
| SCHEMBL28803768 | 0.80 | ALDH1A1 (0.34) | TGM2F13A1TGM1 | |
| SCHEMBL14837788 | 0.79 | TGM2 (0.47) | TGM2F13A1TGM1TGM3HTT | |
| SCHEMBL16990306 | 0.78 | TGM2 (0.52) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL1180685 | 0.76 | TGM2 (0.50) | TGM2F13A1TGM1 | |
| SCHEMBL21873273 | 0.76 | GPR119 (0.50) | HTTATMMEN1KMT2AGPR119 | |
| SCHEMBL28101296 | 0.76 | CKS1B (0.50) | HTTATMGPR119 | |
| SCHEMBL11945569 | 0.74 | TGM2 (0.49) | TGM2F13A1TGM1TGM3MEN1 | |
| SCHEMBL710366 | 0.74 | TGM2 (0.64) | TGM2F13A1TGM1 | |
| SCHEMBL2252120 | 0.73 | TGM2 (0.63) | TGM2F13A1TGM1KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2575815-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC6A5, SLC7A1, AGXT | TGM2 145/4885F13A1 1813/4885TGM1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.